BRCA2 and neoplasm: One of the most dramatic examples of success in this area has been the use of poly-ADP-ribose polymerase (PARP) inhibitors in the treatment of patients with tumours that harbour inactivating mutations in the breast and ovarian cancer susceptibility genes, BRCA1 and BRCA2.